Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage work on genetic strategies aimed at a scalable cure for HIV. Tessera will use the funding to explore multiple genetic modalities that could durably suppress or eliminate HIV reservoirs and that are amenable to broad deployment in resource‑limited settings. The Gates grant signals philanthropic interest in platform genetics approaches with global public‑health implications. Tessera positioned the award as validation of its delivery and genome‑editing toolset to address chronic viral reservoirs at scale. The work remains preclinical; Tessera said the grant will underwrite target validation, delivery optimization, and translational experiments necessary before clinical development can be contemplated.